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Background. We aimed to determine the contemporary causes, clinical features, and short-term outcome of encephalitis in 
Australian children.
Methods. We prospectively identified children (≤14 years of age) admitted with suspected encephalitis at 5 major pediatric 
hospitals nationally between May 2013 and December 2016 using the Paediatric Active Enhanced Disease Surveillance (PAEDS) 
Network. A multidisciplinary expert panel reviewed cases and categorized them using published definitions. Confirmed encephalitis 
cases were categorized into etiologic subgroups.
Results. From 526 cases of suspected encephalitis, 287 children met criteria for confirmed encephalitis: 57% (95% confidence in-
terval [CI], 52%–63%) had infectious causes, 10% enterovirus, 10% parechovirus, 8% bacterial meningoencephalitis, 6% influenza, 
6% herpes simplex virus (HSV), and 6% Mycoplasma pneumoniae; 25% (95% CI, 20%–30%) had immune-mediated encephalitis, 18% 
acute disseminated encephalomyelitis, and 6% anti-N-methyl-d-aspartate receptor encephalitis; and 17% (95% CI, 13%–21%) had an 
unknown cause. Infectious encephalitis occurred in younger children (median age, 1.7 years [interquartile range {IQR}, 0.1–6.9]) com-
pared with immune-mediated encephalitis (median age, 7.6 years [IQR, 4.6–12.4]). Varicella zoster virus encephalitis was infrequent 
following high vaccination coverage since 2007. Thirteen children (5%) died: 11 with infectious causes (2 influenza; 2 human herpes-
virus 6; 2 group B Streptococcus; 2 Streptococcus pneumoniae; 1 HSV; 1 parechovirus; 1 enterovirus) and 2 with no cause identified. 
Twenty-seven percent (95% CI, 21%–31%) of children showed moderate to severe neurological sequelae at discharge.
Conclusions. Epidemic viral infections predominated as causes of childhood encephalitis in Australia. The leading causes in-
clude vaccine-preventable diseases. There were significant differences in age, clinical features, and outcome among leading causes. 
Mortality or short-term neurological morbidity occurred in one-third of cases.
Keywords. encephalitis; child; infant; neonate; epidemiology.
Encephalitis, particularly from infectious diseases, is recognized 
as causing a considerable disease burden [1]. Improving its di-
agnosis and management is a major challenge [2]. Encephalitis 
occurs most commonly in children, yet children make up a mi-
nority of cases in large prospective epidemiological studies per-
formed since 1998 [3–5]. There are few prospective, multicenter 
pediatric studies and none since publication of an international 
case definition [1]. Retrospective or single-center studies are 
likely hampered by sampling biases when assessing the etiolog-
ical spectrum and severity of disease [1], and there are limi-
tations to using administrative datasets [6–8]. Furthermore, 
the impact of comprehensive vaccination programs and the 
increasing recognition of antibody-mediated encephalitides 
have altered epidemiology in high-income settings [1, 6].
We therefore sought to undertake a national, prospective 
study of Australian children hospitalized with encephalitis. We 
aimed to describe the etiological spectrum (including infec-
tious, immune-mediated, and unknown causes), compare the 
clinical features of known causes with that of unknown cause, 
and investigate risk factors for short-term adverse outcomes.
METHODS
The Australian Childhood Encephalitis (ACE) study is a 
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partnership with the Paediatric Active Enhanced Disease 
Surveillance (PAEDS) network [9]. The study methodology and 
evaluation of a pilot study has been recently described [10]. The 
study commenced in 2013 in New South Wales and then from 
2014 extended to include 5 tertiary pediatric hospitals (www.
paeds.edu.au). For additional methodological detail, see the 
Supplementary Materials.
For this analysis, all suspected encephalitis cases were ex-
tracted from their inclusion in surveillance until 31 December 
2016. The investigation and management of individual cases 
was at the discretion of treating physicians. Individual case data 
were reviewed by an expert pediatric panel. Cases were categor-
ized as “confirmed encephalitis” or “not encephalitis” [10], and 
further categorized into etiological groups using Granerod et 
al’s criteria [11]. We re-reviewed magnetic resonance imaging 
(MRI) scans from children provisionally categorized as having 
acute disseminated encephalomyelitis (ADEM) [12, 13]. Cases 
were allocated to 1 of 3 etiological groups (infectious, immune-
mediated, and unknown) for comparative analyses.
Demographics, clinical data, and etiology were compared 
between 2 outcome categories (“good recovery” = Glasgow 
Outcome Score [GOS] of 5; “death or neurological morbidity” 
= GOS of 1 [death] + GOS of 2–4) using multivariable logistic 
regression analysis including cases with complete data.
RESULTS
Population
From 2013 to 2016, we identified 526 children aged ≤14 years 
with suspected encephalitis at 5 hospitals. Of these, 287 chil-
dren were categorized as having confirmed encephalitis (55% 
of suspected cases; Figure 1). The 239 cases categorized as “not 
encephalitis” included both infectious and immune-mediated 
central nervous system (CNS) diseases (Figure 1).
The demographic characteristics of those with confirmed 
childhood encephalitis were compared across the 3 major 
etiological subgroups (Supplementary Table 1 and Figure 
2). Overall, 56% of cases were male; with no significant dif-
ference between groups. The median age of children with in-
fectious encephalitis (1.7 years [interquartile range {IQR}, 
0.09–6.9]) was significantly (P < .001) younger than children 
with immune-mediated encephalitis (7.1 years [IQR, 2.4–9.8]) 
(Supplementary Table 1 and Figure 2). Most infectious enceph-
alitis cases occurred in children aged ≤4 years (70%; with 43% 
aged <1 year); only 26% of immune-mediated encephalitis oc-
curred in this age range. Less than 5% of children had preex-
isting neurological disease or immunocompromise. There were 
no geographic differences in the distribution of etiological sub-
groups (Supplementary Table 1).
Etiology
Of confirmed encephalitis cases, 57% (95% confidence interval 
[CI], 52%–63%; n = 165) had infectious causes, 25% (95% CI, 
20%–30%; n = 73) immune-mediated causes, and 17% (95% CI, 
13%–21%; n = 49) an unknown cause (Table 1). Among infectious 
encephalitis, the leading causes were parechovirus (10%; n = 29), 
enteroviruses (10%; n = 29), influenza (6%; n = 18), herpes sim-
plex virus (HSV) (6%; n = 17), and Mycoplasma pneumoniae (6%; 
n = 16). Of the 8% (n = 22) with bacterial meningoencephalitis, 
Streptococcus pneumoniae and group B Streptococcus (GBS) were 
predominant, with single cases caused by other bacteria (Table 1).
These leading causes of infectious encephalitis were all “con-
firmed” or “probable” causes using the Granerod et al criteria 
except for influenza, enteroviruses, and M. pneumoniae (Table 
1).  A small number of cases were associated (“probable” or 
“possible” cause) with Epstein-Barr virus (EBV), human her-
pesvirus 6 (HHV-6), Murray Valley encephalitis virus (MVEV), 
adenovirus, and respiratory syncytial virus (RSV). Other infec-
tious causes occurred as single cases and were “possible” causes 
using the Granerod et al criteria.
Among the immune-mediated encephalitis cases were 2 pre-
dominant causes (Table 1): ADEM (18%; n = 51) and anti-N-
methyl-d-aspartate receptor encephalitis (anti-NMDAR) (6%; 
n = 17). We identified 1 case of anti-glutamic acid decarboxylase 
antibody encephalitis. Four cases were categorized as immune-
mediated “other” (all relapsing inflammatory brain disease but 
not juvenile-onset multiple sclerosis; Table 1). The causes among 
young infants aged <1 year and cases with immunocompromise 
are detailed in Supplementary Tables 2 and 3.
There were 2 patients with of HSV encephalitis who subse-
quently (≤4 weeks) developed anti-NMDAR encephalitis: 12% 
(95% CI, 8%–16%; n = 2/17) of all HSV cases and 15% (2/13) 
of nonneonatal cases. These were categorized as infectious en-
cephalitis, although noted as additional immune-mediated 
cases (Table 1). Of the ADEM cases, 12 (24%) showed evidence 
of possible associated infection: 3 with serological evidence 
of acute M. pneumoniae, 3 with serological evidence of recent 
EBV, and 6 with polymerase chain reaction (PCR) detection of a 
virus from a nonsterile site (2 enterovirus, 1 adenovirus, 1 RSV, 
and 2 with multiple pathogens).
The clinical features of the cases are shown in Supplementary 
Table 2. No feature was present in all children. Those reported 
most frequently were lethargy (90%), fever (74%), altered per-
sonality/behavior (73%), seizure with loss of consciousness 
(45%), reduced GCS (43%), and a focal neurological sign (45%). 
If tested, abnormality was found most frequently on electro-
encephalography (EEG) (83%), followed by MRI (73%), then 
cerebrospinal fluid (CSF) (pleocytosis in 66%). No specific clin-
ical features were overrepresented in the unknown encephalitis 
group (Supplementary Table 4). Furthermore, there were no 
features on exposure history overrepresented in the unknown 
encephalitis group (Supplementary Table 5). Overall, etiological 
testing among cases of childhood encephalitis was incomplete 
compared with national guidelines published after study com-
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Leading Causes—Epidemiology and Clinical Features
Eight specific causes accounted for more than two-thirds (69%) 
of all confirmed encephalitis cases: 6 infectious (enteroviruses, 
parechovirus, HSV, influenza, M. pneumoniae, “bacterial” me-
ningoencephalitis) and 2 immune-mediated (ADEM and anti-
NMDAR). Among the leading infectious causes, many occurred 
in association with defined epidemic periods (Supplementary 
Figure 1) [15–19]. Five of 29 (17%) enteroviral cases occurred 
during the EVA71 epidemic in 2013 [15]. Other enteroviral 
cases occurred in late autumn and spring/early summer. All 
parechovirus cases occurred during 2 epidemics in 2013–2014 
and 2015–2016 [16, 17, 20]. Influenza-associated encepha-
litis only occurred during the southern hemisphere influenza 
season [18]. A cluster of M. pneumoniae encephalitis occurred 
in New South Wales between July and October 2015 [19]. HSV 
encephalitis was an exception, occurring sporadically across the 
surveillance period. There was no clear clustering or seasonality 
among ADEM cases (Supplementary Figure 1).
The clinical features, severity, and outcome of these leading 
infectious and immune-mediated causes of encephalitis 
Figure 1. Flowchart showing categorization of childhood (age ≤14 years) suspected encephalitis cases identified by the Australian Childhood Encephalitis study, 2013–
2016. The 3 cases categorized as neonatal herpes simplex virus (HSV) were babies at risk, investigated early, and had HSV DNA detected in cerebrospinal fluid without clinical 
features of encephalitis. In the absence of early investigation and treatment, these cases may have progressed. *One Neisseria meningitidis, 9 parechovirus (PeV), 2 enter-
ovirus (EV), 1 EV + PeV, 1 nil cause. **One clinically isolated syndrome (CIS), 1 probable NMO. ***One CIS. ****Two CIS, 1 postradiotherapy demyelination. Abbreviations: 
CVA, cerebrovascular accident; HIE, hypoxic ischemic encephalopathy; HLH, hemophagocytic lymphohistiocytosis; HSV, herpes simplex virus; NMO, neuromyelitis optica; 
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are shown in Table 2. Age differed significantly. All cases of 
parechovirus encephalitis occurred in children aged <1 year 
(median age, 0.06 years). Enteroviruses, HSV, and influenza 
encephalitis occurred primarily in preschool-aged children 
(75%, 73%, and 80% aged ≤4 years, respectively). An excep-
tion among infectious causes was M. pneumoniae–associ-
ated encephalitis (median age, 9.1 years). Immune-mediated 
encephalitis occurred in older children; ADEM and anti-
NMDAR occurred in children with median ages of 6.8 and 
10.1 years, respectively (Table 2). There were significant differ-
ences in the core features of encephalitis among these leading 
causes (Table 2).
Outcome at Discharge
Disease severity and outcomes are shown in Supplementary 
Table 7. Intensive care unit (ICU) admission occurred in 49%, 
and was more frequent in infectious and unknown causes 
than immune-mediated encephalitis. Median length of hospi-
talization was 11 days, with a higher proportion of immune-
mediated cases requiring prolonged hospitalization (>14 days; 
Supplementary Table 5). Fourteen children died, 13 directly at-
tributable to encephalitis (13/287; case fatality proportion 5% 
[95% CI, 2%–7%]); 11 from infectious encephalitis (2 influ-
enza, 2 HHV-6, 2 GBS, 2 S. pneumoniae, 1 HSV, 1 parechovirus, 
1 enterovirus) and 2 with encephalitis of unknown cause. 
Twenty-seven percent of children showed moderate to severe 
neurodisability at discharge from hospital (GOS ≤ 4).
Risk Factors for Adverse Outcome
Several factors were associated with adverse outcome when 
stratified by GOS at discharge (Table 3; Supplementary Table 
8).  Seizure with loss of consciousness (odds ratio [OR], 2.4), 
Glasgow Coma Scale (GCS) score <13 (OR, 3.5), abnormal EEG 
(OR, 2.9), and ICU admission (OR, 3.3) were all associated with 
neurological morbidity or death. Having encephalitis caused 
by bacterial infection (OR, 2.9), HSV (OR, 6.0), influenza (OR, 
4.2), anti-NMDAR (OR, 4.7), or ADEM (OR, 2.7) was associ-
ated with adverse outcome (Table 3). In a multivariable logistic 
regression model, the following factors remained statistically 
significantly associated with adverse outcome: HSV (OR, 20.3), 
influenza (OR, 12.1), anti-NMDAR (OR, 24.5) or ADEM (OR, 
11.5), and the clinical features of reduced GCS (OR, 2.9) and 
admission to ICU (OR, 6.5) (Table 3).
DISCUSSION
The Australian Childhood Encephalitis study is the largest pro-
spective cohort of all-cause childhood encephalitis in the world, 
and the first study of its kind in the Southern Hemisphere. It is 
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distinct in including children from birth, not only those aged 
>6 months [1]. In contrast to the larger California Encephalitis 
Project cohort, it recruited all children hospitalized with syn-
dromes suggestive of encephalitis, not selected cases referred for 
further investigation [3, 21]. The cohort was recruited using ac-
tive hospital-based surveillance—the PAEDS Network—which, 
although not population-based, is nationally representative, 
including the largest pediatric hospitals in the most populous 
Australian states [22].
We have definitively shown that the leading causes of child-
hood encephalitis in Australia are enteroviruses, parechovirus, 
HSV, influenza, M. pneumoniae, Streptococcus species, ADEM, 
and anti-NMDAR. By comparison, several large prospective 
cohort studies in predominantly adults from high-income 
countries showed the leading causes of adult encephalitis to be 
HSV, varicella zoster virus (VZV), Mycobacterium tuberculosis, 
Listeria monocytogenes, and anti-NMDAR (Supplementary 
Table 9) [3–5]. In these studies, enteroviruses, EBV, M. 
pneumoniae, and ADEM were more frequent in children [3, 5]. 
Furthermore, we have shown that age was a key determinant of 
cause across childhood. Parechovirus, enteroviruses, and bac-
terial meningoencephalitis predominate in young infants. In 
older infants and toddlers, enteroviruses, influenza, and HSV 
predominate. Among children and young adolescents, ADEM, 
Table 1. Causes of Childhood (Age ≤14 Years) Encephalitis Identified by the Australian Childhood Encephalitis Study, 2013–2015
Cause Confirmed/Probablea Possible
Total No. (%) or 
No. (% [95% CI])
Suspected encephalitis … … 526
Confirmed encephalitis (% suspected encephalitis) … … 287 (55)
Infectious 101 (35 [30–41]) 64 (22 [18–27]) 165 (57 [52–63])
Parechovirus 28 1 29 (10 [7–14])
Enterovirus 17 12 29 (10 [7–13])
“Bacterial” b meningoencephalitis 22 … 22 (8 [5–11])
Influenza … 18 18 (6 [3–9])
HSV 17 … 17 (6 [3–9])
Mycoplasma pneumoniae 12 4 16 (6 [3–8])
HHV-6 1 2 3 (1)
EBV 2 … 2 (1)
MVEV 1 1 2 (1)
CMV 1 … 1 (<1)
RSV … 3 3 (1)
Adenovirus … 2 2 (1)
VZV … 1 1 (<1)
HMPV … 1 1 (<1)
Norovirus … 1 1 (<1)
Rotavirus … 1 1 (<1)
Cryptococcus species … 1 1 (<1)
Toxocariasis … 1 1 (<1)
Mixedc … 15 15 (5 [3–8])
Immune-mediated 73 … 73 (25 [20–30])
ADEM 51 … 51 (18 [13–22])
Anti-NMDAR 17 (2)d … 17 (6 [3–9])
Anti-GAD 1 … 1 (<1)
Othere 4 … 4 (1)
Unknown 49 … 49 (17 [13–21])
Abbreviations: ADEM, acute disseminated encephalomyelitis; CI, confidence interval; CMV, cytomegalovirus; EBV, Epstein-Barr virus; GAD, glutamic acid decarboxylase; HHV-6, human 
herpesvirus type 6; HMPV, human metapneumovirus; HSV, herpes simplex virus; MVEV, Murray Valley encephalitis virus; NMDAR, N-methyl-d-aspartate receptor; RSV, respiratory syncytial 
virus; VZV, varicella zoster virus.
aAll cases of enterovirus, parechovirus, and HSV encephalitis were confirmed (by detection of viral nucleic acid in cerebrospinal fluid [CSF]). All but 3 cases of bacterial meningoencephalitis 
were confirmed (cultured from CSF); in 3 a blood culture specimen was positive in addition to CSF, clinical, or imaging findings of meningitis. The CMV case was confirmed (posttransplant, 
CMV polymerase chain reaction [PCR] positive in CSF and blood with positive immunoglobulin M [IgM]). All mycoplasma cases were probable (serum IgM positive).The HHV-6 (posttransplant 
encephalitis with detection of viral nucleic acid in CSF), MVEV (1 IgM positive AND immunoglobulin G positive in acute sera; 1 seroconversion), and CMV cases in this column were probable. 
One EBV case was confirmed (detection of viral nucleic acid in CSF and serology suggesting acute infection) and 1 was probable (detection of viral nucleic acid in CSF only).
bStreptococcus pneumoniae (n = 8); group B Streptococcus (S. agalactiae) (n = 7); Neisseria meningitidis (n = 1); group A Streptococcus (S. pyogenes) (n = 1); Escherichia coli (n = 1); 
Citrobacter freundii (n = 1); Enterobacter cloacae (n = 1); Listeria monocytogenes (n = 1); Salmonella species (n = 1).
cThese included multiple viruses identified using multiplex PCR testing on respiratory specimens, or 1 virus detected in combination with positive serology for Mycoplasma pneumoniae. 
^Probable autoinflammatory central nervous system disorder (n = 1); antimyelin oligodendrocyte-associated encephalitis (n = 2); relapsing demyelinating disorder not otherwise specified 
(n = 1).
dThese 2 cases occurred following (≤4 weeks) confirmed HSV encephalitis. The cases have been categorized as cases of HSV encephalitis in this table and are not included in the propor-
tional contribution of anti-NMDAR encephalitis.
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anti-NMDAR, and M. pneumoniae predominate. A similar as-
sociation of age with etiology was shown in a retrospective, 
single-center cohort from Australia, although influenza was in-
frequent and parechovirus absent in that study [23]. Location 
remains significant in determining cause with respect to en-
demic flaviviruses; 2 of our cases were caused by MVEV, both 
from Northern Australia. In Asia, Japanese encephalitis virus 
predominates in childhood encephalitis [24, 25], and in parts of 
Europe, tickborne encephalitis virus is prominent [26]. Another 
key finding was that VZV was unexpectedly infrequent as a 
cause in this cohort. This is likely due to high varicella vac-
cine coverage and effectiveness in Australia since inclusion in 
the National Immunisation Program in 2007 [6, 27]. We also 
note that acute cerebellar ataxia was specifically excluded from 
encephalitis categorization, although VZV was not implicated 
even in excluded cases (Figure 1).
Encephalitis is an uncommon and severe disease with pro-
tean manifestations. Clinician investigation and management 
tend to be suboptimal [28, 29]. We have shown significant 
differences in the clinical features between the leading causes 
of childhood encephalitis. Few previous studies have com-
pared clinical features between subgroups [23]. Our findings 
contribute to supporting clinicians in the diagnosis, empiric 
treatment, and early investigation of suspected encephalitis in 
children. Furthermore, we have identified that a substantial 
proportion of infectious encephalitis in Australian children 
occurred in epidemics. This supports ongoing surveillance, 
with timely reporting to increase clinician awareness of disease 
trends, especially in epidemic periods, and support optimal 
management of children with this serious condition.
We have shown that a putative cause is identifiable in up to 
80% of cases of childhood encephalitis (75% if mixed infectious 
cases excluded; 55% if all “possible” infectious cases excluded). 
This is a high proportion compared with previous studies [1], 
and higher than that identified using International Classification 
of Diseases–coded hospitalization data [6]. Prospective case 
ascertainment with detailed case review and categorization 
has contributed to this, as has including young infants (aged 
<6 months) where an infectious etiology is most common. A 
prospective UK study of all-age encephalitis that used similar 
methods had a similarly high proportion of cases with a pu-
tative cause [5]. Additional contributors are the contemporary 
availability of molecular testing (especially for viruses) and in-
creased awareness of antibody mediated encephalitides. Despite 
Table 3. Statistically Significant Factors Associated With Adverse Outcome (Death or Neurological Morbidity) in a Multivariable Logistic Regression 
Model Among Cases of Childhood (Age ≤14 Years) Encephalitis Identified by the Australian Childhood Encephalitis Study, 2013–2015
Predictor Univariate OR (95% CI) P Value Multivariable aOR (95% CI)a P Value
Age, y  .203  .441
 <1 1.0 (.5–2.1)  0.6 (.1–2.4)  
 1–4 1.2 (.6–2.5)  1.0 (.3–2.7)  
 5–9 0.55 (.25–1.2)  0.5 (.2–1.3)  
 ≥10 1.0 (ref)  1.0 (ref)  
Clinical features     
 Fever 0.62 (.35–1.1) .11 0.6 (.2–1.4) ns
 Seizure with LOC 2.4 (1.4–4.0) .001 1.1 (.5–2.5) ns
 Altered personality/behavior 1.6 (.88–2.9) .15 1.6 (.6–4.2) ns
 GCS score <13b 3.5 (1.9–6.4) <.001 2.9 (1.1–7.2) .03
 Abnormal MRI 2.4 (1.2–4.7) .007 Not entered  
 Abnormal EEG 2.9 (1.0–8.2) .03 Not entered  
 ICU admission 3.3 (1.9–5.6) <.001 6.5 (2.0–20.8) .002
Specified leading causes  .001  <.001
 Other 1.0 (ref)  1.0 (ref)  
 Enterovirus 0.87 (.29–2.6)  1.1 (.2–5.4)  
 Parechovirus 1.6 (.60–4.2)  2.6 (.2–21.7)  
 Bacterial 2.9 (1.1–7.9)  2.9 (.6–14.2)  
 Influenza 4.2 (1.4–12.1)  12.1 (2.2–68)  
 HSV 6.0 (2.0–17.9)  20.3 (2.8–151)  
 Mycoplasma 0.28 (.03–2.3)  0.32 (.03–3.4)  
 ADEM 2.7 (1.2–5.8)  11.5 (3.5–38.2)  
 Anti-NMDAR 4.7 (1.6–14.0)  24.5 (4.8–124.5)  
Boldfaced P values show significance at an alpha level of .05. 
Abbreviations: ADEM, acute disseminated encephalomyelitis; aOR, adjusted odds ratio; CI, confidence interval; EEG, electroencephalogram; GCS, Glasgow Coma Scale; HSV, herpes sim-
plex virus; ICU, intensive care unit; LOC, loss of consciousness; MRI, magnetic resonance imaging; NMDAR, N-methyl-d-aspartate receptor; ns, not significant; OR, odds ratio.
aVariables entered: age, fever, seizure with LOC, altered personality/behavior (GCS score <13), ICU admission, specified leading causes. Model parameters: n = 195 (ie, 92 cases with 
missing data). Test of model coefficients: χ 2 = 71.525 at 16 degrees of freedom (P < .001). Nagelkerke R2 = 0.428. Hosmer-Lemeshow P value = 0.850. Prediction percentage in null model 
= 67.2%, in test model = 80.0%. 
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this, 1 in 5 cases of childhood encephalitis had no cause iden-
tified. Even in this study, where diagnostic guidelines specific 
to Australia were published and disseminated, they appear to 
have been incompletely applied [14]. Optimal implementation 
of such guidelines may further reduce the proportion with un-
known cause. However, we also observed several cases where 
extensive diagnostic testing was performed but no diagnosis 
made; new causes may be found, although inadequate sensi-
tivity of current tests cannot be ruled out. A further challenge 
is that there were no clear clinical features or risk factors to dif-
ferentiate these cases from those cases with known causes. New 
approaches to diagnosis in childhood encephalitis are required 
including the use of next-generation sequencing that appears 
promising [30, 31].
A further insight arising from this cohort is the interaction 
of infectious and immune-mediated etiologies. Two cases of 
post-HSV encephalitis, anti-NMDAR encephalitis were ob-
served, an emerging syndrome that is changing paradigms of 
infection-mediated autoimmunity [32]. We offer an estimate 
that anti-NMDAR occurs in 10% of childhood HSV enceph-
alitis (15% if neonatal disease excluded), which is somewhat 
lower than that in a recent study from Spain [33]. Here, cases 
were not systematically tested for antibodies but were found 
on the basis of clinical relapse. Furthermore, we observed se-
rological evidence for recent infection among 14% of ADEM 
cases. ADEM is often associated with infection and frequently 
denoted as a “postinfectious” syndrome, although its pathogen-
esis remains elusive [34]. It is the most frequent cause of child-
hood encephalitis and appears to be increasing in frequency 
[6, 7]. Additionally, the median age of children with immune-
mediated encephalitis was significantly older than those with 
infectious causes. The interaction between age, immune func-
tion, and infectious exposures needs greater attention to ad-
vance our understanding of the pathogenesis of severe CNS 
inflammation [35].
We have shown that short-term outcome at discharge, in-
cluding death, was significantly associated with cause. Severe 
brain injury may result from both true encephalitis (eg, HSV) 
and infection-associated encephalopathy (eg, influenza). The 
contribution of influenza emphasizes that multiple pathways 
of pathogenesis are important in childhood encephalitis syn-
drome; both pathological encephalitis and severe encephalop-
athy contribute to the burden of disease [36]. There is a need to 
better define the pathogenesis of these heterogeneous diseases 
to improve targeting of available therapies. Influenza was inde-
pendently associated with death or neurological morbidity, also 
emphasizing a need for enhanced influenza prevention efforts 
among children.
Our study has considerable strengths. The prospective, ac-
tive case ascertainment ensured a high likelihood that we 
have not missed any cases at participating sites. Equally, dem-
ographic and hospitalization data were complete. Waiver of 
consent ensured that cases resulting in death were included. 
All diagnostic testing data were pursued and fully reviewed 
by the expert panel. However, we acknowledge limitations in 
some collected data because clinical assessment and diagnostic 
testing were at the discretion of attending clinicians and de-
tailed neurological assessment was variable, in part because 
of challenges in evaluating the high proportion of very young 
children. A further potential limitation is that among infec-
tious causes, we have included cases with “possible” causation 
when aggregating the etiological spectrum. The expert panel 
rigorously applied the Granerod et al criteria when categorizing 
cases [11]; however, we have included “possible” causes because 
these criteria may underestimate the causative role of certain 
pathogens. In the case of enteroviruses, there is growing evi-
dence showing the limited sensitivity of CSF nucleic acid detec-
tion in neurotropic enteroviruses including EVA71 and EVD68 
[37, 38]. One study has assigned “probable” causation when 
enterovirus was identified in 2 sites concurrently (respiratory 
and gastrointestinal) to recognize its strength of association 
during encephalitis (occurred in 5 of 12 ACE possible enter-
ovirus cases) [39]. Furthermore, we believe the Granerod et al 
definitions give insufficient weight to causes of infection associ-
ated encephalopathy where the CNS syndrome has arisen from 
brain inflammation triggered by an infection elsewhere (in-
direct pathogenesis). In the case of influenza, during seasonal 
epidemics where a clinicoradiological syndrome such as acute 
necrotizing encephalopathy is observed in association with in-
fluenza [36], many would consider its causative role to be at 
least “probable” [40]. This applies to the majority of influenza-
associated encephalitis cases described here. Other childhood 
infections for which this is an important consideration include 
rotavirus, norovirus, RSV, and HHV-6 [41, 42]. In contrast, 
the detection of β- and γ-herpesviruses (EBV, CMV, HHV-6) 
by PCR in CSF may overestimate their significance [43]. This 
is particularly the case where timely serology is lacking, and 
for HHV-6 where chromosomal integration is not excluded 
[11]. One case each of “probable” EBV encephalitis and “pos-
sible” HHV-6 encephalitis were subject to these limitations. A 
further important controversy surrounds the attribution of M. 
pneumoniae as a cause partly because of inherent limitations 
with available diagnostic tests [19, 44, 45]. Here, all cases were 
diagnosed serologically, did not have alternative causes, and did 
not have imaging consistent with ADEM as per Granerod et al. 
We acknowledge that the reporting of “possible” causes is most 
problematic when >1 pathogen was identified (“mixed” infec-
tious encephalitis in Table 1).
A further limitation is that a definitive, long-term outcome 
is yet to be characterized in this cohort. Twenty-seven percent 
of children showed neurodisability at discharge using the GOS. 
The GOS is validated for use in traumatic brain injury and was 
used for simplicity, although we acknowledge that for encepha-
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to analyze it as a binary outcome measure only. It cannot be con-
sidered predictive of long-term outcome. We note that for both 
anti-NMDAR and ADEM, the short-term outcomes reported 
here likely do not correlate with the expected medium-term re-
covery in many cases [34, 46]. A recent systematic review of the 
long-term outcome of childhood infectious encephalitis showed 
that incomplete recovery was reported in 42.0% of cases (95% 
CI, 32%–53%; pooled estimate) [47]. The short-term outcomes 
reported likely underestimate the overall neurodevelopmental 
sequelae in this cohort.
CONCLUSIONS
This is one of the largest and most rigorous studies of childhood 
encephalitis. The most common specific causes were entero-
viruses, parechovirus, HSV, influenza, M. pneumoniae, ADEM, 
and anti-NMDAR; one-fifth of cases had an unknown cause. 
This severe disease continues to cause death in 1 in 20 affected 
children, and results in considerable neurological morbidity 
among survivors.
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